• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

    2/27/25 4:01:00 PM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNLI alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.

    "In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle (ETV) programs, achieving a path to a potential accelerated approval for our lead program in MPS II," said Ryan Watts, Ph.D., CEO of Denali. "In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and aim to advance one to two programs to the clinic annually."

    Fourth Quarter 2024 and Recent Program Updates

    CLINICAL PROGRAMS

    Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II)

    In February 2025, Denali presented results of the primary analysis of the Phase 1/2 study in Hunter syndrome, in addition to long-term data in the ongoing study. The data showed robust and sustained reductions in key biomarkers, along with continued improvements in hearing, cognition, and adaptive behavior. Long-term safety results indicated tividenofusp alfa was generally well tolerated.

    Denali remains on track to submit a Biologics License Application (BLA) under the accelerated approval pathway in early 2025 and is preparing for a U.S. commercial launch in late 2025 or early 2026. The FDA Breakthrough Therapy designation, granted in January 2025, provides enhanced regulatory support, including more intensive FDA guidance and eligibility for rolling submission and priority review.

    Denali is actively advancing prelaunch activities to support tividenofusp alfa and potential future ETV programs. These efforts include engaging with prescribers and payers, developing a suite of patient support services to ensure broad access, and building a targeted commercial and medical affairs team.

    The company continues to enroll patients in the global Phase 2/3 COMPASS study, which aims to support global regulatory approvals. In January 2025, Denali expanded target enrollment for neuronopathic participants (Cohort A) to 42 patients, reflecting steady progress in recruitment and data collection.

    DNL126 (ETV:SGSH) for Sanfilippo syndrome Type A (MPS IIIA)

    Following initial positive Phase 1/2 results demonstrating proof of concept for Sanfilippo syndrome, Denali plans to engage with the FDA to align on a pathway for accelerated approval of DNL126. The Phase 1/2 study continues to enroll participants with Sanfilippo syndrome.

    DNL126 has received FDA Orphan Disease designation and Fast Track status and has been selected for the FDA's Support for clinical Trials Advancing Rare disease Therapeutics (START) program. This pilot initiative aims to accelerate the development of rare disease treatments.

    TAK-594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia

    Dosing of participants continues in the Phase 1/2 study of DNL593 in the treatment of progranulin (GRN)-related frontotemporal dementia (FTD-GRN).

    DNL343 (small molecule eIF2B agonist) for the treatment of amyotrophic lateral sclerosis (ALS)

    In January 2025, Denali announced topline results that the primary endpoint was not met in the HEALEY ALS platform trial. Further analyses are anticipated later in 2025, including neurofilament light (NfL) and other fluid biomarkers, data from pre-specified subgroups, as well as extended findings from the active treatment extension period.

    BIIB122/DNL151 (small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD)

    Denali and Biogen are jointly developing LRRK2 small molecule inhibitors. Biogen is leading the global Phase 2b LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD, with enrollment of approximately 640 participants expected to complete in 2025. Denali is conducting the Phase 2a BEACON study, specifically enrolling participants with LRRK2-associated PD to assess how LRRK2 inhibition may impact this disease. Dosing in BEACON began in December 2024.

    IND-ENABLING STAGE PROGRAMS

    Denali is building a broad portfolio of therapeutic candidates by investing in parallel across its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Beginning in 2025, Denali expects to advance one to two additional programs to the clinic per year over the next three years across its TV-enabled franchises (ETV, OTV, and ATV). IND-enabling stage programs include:

    ETV

    • DNL952 (ETV:GAA) for Pompe disease
    • DNL111 (ETV:GCase) for Parkinson's disease and Gaucher disease
    • DNL622 (ETV:IDUA) for Hurler syndrome (MPS I)

    ATV

    • DNL921 (ATV:Abeta) targeting amyloid beta for Alzheimer's disease

    OTV

    • DNL628 (OTV:MAPT) targeting tau for Alzheimer's disease
    • DNL422 (OTV:SNCA) targeting alpha synuclein for Parkinson's disease

    2025 Guidance on Operating Expenses

    Cash, cash equivalents, and marketable securities were approximately $1.19 billion as of December 31, 2024. For 2025, Denali anticipates an increase of approximately 10% to 15% in cash operating expenses compared to 2024.

    Participation in Upcoming Investor Conferences

    • TD Cowen 45th Annual Health Care Conference, March 3 - 5
    • Leerink Partners Global Healthcare Conference, March 9 - 12
    • Jefferies Biotech on the Beach, March 11 - 12
    • UBS Virtual CNS Day 2025, March 17
    • Stifel CNS Days 2025, March 18 - 19

    Fourth Quarter and Full Year 2024 Financial Results

    Net losses were $114.8 million and $422.8 million for the quarter and year ended December 31, 2024, respectively, compared to net losses of $119.5 million and $145.2 million for the quarter and year end December 31, 2023, respectively.

    There was no collaboration revenue for the quarters ended December 31, 2024 and December 31, 2023. There was no collaboration revenue for the year ended December 31, 2024, compared to $330.5 million for the year ended December 31, 2023. The decrease in collaboration revenue of $330.5 million for the year ended December 31, 2024 compared to the previous year was primarily due to $293.9 million in revenue recognized in April 2023 under the Biogen Collaboration Agreement as a result of Biogen exercising its option to license our ATV:Abeta program, as well as decreases in revenue earned under the Sanofi and Takeda Collaboration Agreements of $25.0 million and $10.0 million, respectively, due to the timing of underlying activities and achievement of milestones under the collaboration agreements.

    Total research and development expenses were $99.8 million and $396.4 million for the quarter and year ended December 31, 2024, respectively, compared to $107.8 million and $423.9 million for the quarter and year ended December 31, 2023, respectively. The decrease of approximately $8.0 million and $27.4 million for the quarter and year ended December 31, 2024, respectively, compared to the comparative period in the prior year were primarily attributable to decreases in personnel-related expenses, including decreases in salary and stock-based compensation expenses, other research and development expenses, as well as decreases in small molecule programs and other external expenses, primarily driven by the divestiture of our preclinical small molecule programs in March 2024 and focus on the Company's TV-enabled portfolio.

    General and administrative expenses were $30.1 million and $105.4 million and for the quarter and year ended December 31, 2024, respectively compared to $24.8 million and $103.4 million for the quarter and year end December 31, 2023 respectively. The increase in expense in the periods ending December 31, 2024 was primarily driven by activities related to the planned submission of a BLA for tividenofusp alfa in early 2025 and preparations for a commercial launch in late 2025 or early 2026.

    About Denali Therapeutics

    Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations regarding Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including enrollment in the ongoing global Phase 2/3 COMPASS study and the likelihood of global approvals, the timing of planned regulatory filings, and the timing, likelihood, and scope of regulatory approvals and commercial launch; plans, timelines, and expectations related to DNL126, including enrollment in the ongoing Phase 1/2 study, planned engagement with the FDA, and the likelihood and scope of regulatory approvals; plans, timelines, and expectations regarding DNL593 and the ongoing Phase 1/2 study; plans regarding DNL343 including the timing and availability of further analysis; plans, timelines, and expectations regarding DNL151, including with respect to the ongoing Phase 2a LUMA study and Phase 2b BEACON study and enrollment in both studies; plans and expectations for Denali's preclinical programs, including the timing of advancement to clinical studies; Denali's future operating expenses and anticipated cash runway; and Denali's participation in upcoming investor conferences. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: any and all risks to Denali's business and operations caused by adverse economic conditions; risk of the occurrence of any event, change, or other circumstance that could give rise to the termination of Denali's agreements with Sanofi, Takeda, or Biogen, or any of Denali's other collaboration agreements; Denali's transition to a late-stage clinical drug development company; Denali's and its collaborators' ability to complete the development and, if approved, commercialization of its product candidates; Denali's and its collaborators' ability to enroll patients in its ongoing and future clinical trials; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; Denali's dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates; Denali's and its collaborators' ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali's product candidates may not translate in clinical trials; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities or other undesirable side effects; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali's ability to continue to create a pipeline of product candidates or develop commercially successful products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates, and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024 and November 6, 2024, respectively, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law.



    Denali Therapeutics Inc.


    Condensed Consolidated Statements of Operations

    (Unaudited)

    (In thousands, except share and per share amounts)

     Three Months Ended December 31, Twelve Months Ended December 31,
     2024 2023 2024 2023
    Collaboration revenue:       
    Collaboration revenue from customers(1)$—  $—  $—  $330,531 
    Total collaboration revenue —   —   —   330,531 
    Operating expenses:       
    Research and development(2) 99,787   107,803   396,440   423,876 
    General and administrative 30,059   24,769   105,438   103,354 
    Total operating expenses 129,846   132,572   501,878   527,230 
    Gain from divestiture of small molecule programs —   —   14,537   — 
    Loss from operations (129,846)  (132,572)  (487,341)  (196,699)
    Interest and other income, net 15,161   13,129   64,636   51,505 
    Loss before income taxes (114,685)  (119,443)  (422,705)  (145,194)
    Income tax expense (68)  (30)  (68)  (30)
    Net loss$(114,753) $(119,473) $(422,773) $(145,224)
    Net loss per share, basic and diluted$(0.67) $(0.86) $(2.57) $(1.06)
    Weighted average number of shares outstanding, basic and diluted 170,086,146   138,245,382   164,473,772   137,370,897 
                    

    __________________________________________________

    (1)   Includes related-party collaboration revenue from customers of $295.5 million for the twelve months ended December 31, 2023.

    (2)   Includes expenses for cost sharing payments due to a related party of $17.7 million for the twelve months ended December 31, 2023.



    Denali Therapeutics Inc.


    Condensed Consolidated Balance Sheets

    (Unaudited)

    (In thousands)

     December 31, 2024 December 31, 2023
    Assets   
    Current assets:   
    Cash and cash equivalents$174,960 $127,106
    Short-term marketable securities 657,371  907,405
    Prepaid expenses and other current assets 32,105  29,626
    Total current assets 864,436  1,064,137
    Long-term marketable securities 359,373  —
    Property and equipment, net 55,236  45,589
    Finance lease right-of-use asset 47,533  —
    Operating lease right-of-use asset 22,861  26,048
    Other non-current assets 24,741  18,143
    Total assets$1,374,180 $1,153,917
    Liabilities and stockholders' equity    
    Current liabilities:   
    Accounts payable$11,137 $9,483
    Accrued expenses and other current liabilities 91,071  68,499
    Total current liabilities 102,208  77,982
    Operating lease liability, less current portion 36,673  44,981
    Finance lease liability, less current portion 5,615  —
    Total liabilities 144,496  122,963
    Total stockholders' equity 1,229,684  1,030,954
    Total liabilities and stockholders' equity$1,374,180 $1,153,917
          

    Investor Contact:

    Laura Hansen, Ph.D.

    Vice President, Investor Relations

    [email protected]

    (650) 452-2747

    Media Contact:

    Rich Allan

    FGS Global

    [email protected]

    (503) 851-0807



    Primary Logo

    Get the next $DNLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNLI

    DatePrice TargetRatingAnalyst
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    2/11/2025$31.00Buy
    Deutsche Bank
    1/7/2025$31.00Outperform
    Robert W. Baird
    1/3/2025Outperform
    William Blair
    12/16/2024$37.00Hold → Buy
    Stifel
    10/10/2024Mkt Perform
    Raymond James
    10/7/2024Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $DNLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

      Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval for tividenofusp alfaProductive collaboration continues under START for an accelerated development and approval path for DNL126 SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has bee

      4/2/25 8:00:44 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. "In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle (ETV) programs, achieving a path to a potential accelerated approval for our lead program in MPS II," said Ryan Watts, Ph.D., CEO of Denali. "In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and a

      2/27/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ho Carole sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 8% to 175,673 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:26:37 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COFO and Secretary Schuth Alexander O. sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 6% to 244,308 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:25:44 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Watts Ryan J. sold $750,955 worth of shares (36,916 units at $20.34), decreasing direct ownership by 13% to 253,071 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:24:43 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

      Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously

      3/7/25 8:22:55 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Denali Therapeutics with a new price target

      Deutsche Bank initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $31.00

      2/11/25 7:04:19 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Denali Therapeutics Inc.

      SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 12:52:28 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 9:55:15 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/8/24 10:52:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Denali Therapeutics Inc.

      10-Q - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:04:50 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:03:05 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Denali Therapeutics Inc.

      DEFA14A - Denali Therapeutics Inc. (0001714899) (Filer)

      4/17/25 4:06:10 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

      O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar

      4/8/24 8:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

      Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors  CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be

      1/9/24 8:44:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

      Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.

      11/27/23 7:01:00 PM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations